Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2011 Dec;85(6):1035-7.
doi: 10.4269/ajtmh.2011.11-0449.

Case report: Acute renal injury as a result of liposomal amphotericin B treatment in sodium stibogluconate unresponsive visceral leishmaniasis

Affiliations
Case Reports

Case report: Acute renal injury as a result of liposomal amphotericin B treatment in sodium stibogluconate unresponsive visceral leishmaniasis

Songtao Zhao et al. Am J Trop Med Hyg. 2011 Dec.

Abstract

We report an unusual case of visceral leishmaniasis occurring in a patient from Sichuan China. The patient presented with a remitting fever, anemia, and pancytopenia. The case was confirmed as visceral leishmaniasis by microscopical detection of the Leishmania species amastigote in bone marrow aspirate. The patient was treated with 10 mg/kg/day of sodium stibogluconate for 5 days, with no therapeutic response. As a result, the patient was treated with liposomal amphotericin B (LAB) at 10 mg/day as an initial dosage. After treatment with an increasing drug dosage for 7 days, acute renal injury was evident as indicated by increased serum creatinine and urea nitrogen. LAB administration was discontinued until serum creatinine and serum urea nitrogen regressed on Day 15. Two maintenance treatments of 100 mg/day LAB were given on Days 19 and 26 (total 870 mg, 14.5 mg/kg). Bone marrow aspirate and clinical examination suggested total remission.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Bone marrow biopsy revealed characteristic Leishmania amastigotes either extracellularly or within bone marrow macrophages (Giemsa stain; original magnification, ×400).

Similar articles

Cited by

References

    1. Zhang LP, Zhang FN. Epidemiological and clinical analysis of 166 kala-azar cases. Parasites Infect Dis. 2010;18:181–186.
    1. Killick-Kendrick R. Education is key to controlling visceral leishmaniasis. Bull World Health Organ. 2010;88:11–12. - PMC - PubMed
    1. Mondal S, Bhattacharya P, Ali N. Current diagnosis and treatment of visceral leishmaniasis. Expert Rev Anti Infect Ther. 2010;8:919–944. - PubMed
    1. Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P, Modabber F. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomized controlled trial. Lancet. 2011;377:477–486. - PubMed
    1. Kang X, Liu Y, Liu K, Lu X. Human leishmaniasis: a retrospective clinical analysis of 86 patients. Chin J Infect Chemother. 2009;9:241–243.

Publication types

MeSH terms